Table 1 Clinicopathological characteristics of the 227 patients with stage II colorectal carcinoma included in this study
From: Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients
| Â | Frequency (n) | Percentage (%) |
|---|---|---|
Patients | 227 | Â |
Age (years) | Â | |
 Media | 68.3 ± 11.5 | |
 Range | 23–92 | |
Sex | ||
 Female | 92 | 40.5 |
 Male | 135 | 59.5 |
Histopathological grade | ||
 G1 | 4 | 1.8 |
 G2 | 210 | 93.7 |
 G3 | 10 | 4.5 |
 Mucinous | 3 |  |
Tumor Location | ||
 Proximal colon | 75 | 33.5 |
 Distal colon | 107 | 47.8 |
 Rectum | 42 | 18.7 |
 ND | 3 |  |
Chemotherapy | ||
 Neo-Adjuvant | ||
 Yes | 11 | 4.8 |
 No | 216 | 95.2 |
Adjuvant | ||
 Yes | 34 | 15.4 |
 No | 187 | 84.6 |
 ND | 6 |  |
Resection margins | ||
 R0 | 179 | 98.9 |
 R1/R2 | 2 | 1.1 |
 ND | 46 |  |
BRAF V600E | ||
 WT | 186 | 86.1 |
 MUT | 30 | 13.9 |
 ND | 11 |  |
Mismatch repair status | ||
 MMR-deficient | 91 | 43.5 |
 MMR-proficient | 118 | 56.5 |
 ND | 18 |  |